Polycythemia Vera - Pipeline Insight, 2026

This “Polycythemia Vera - Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Polycythemia Vera pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Polycythemia Vera: Understanding

Polycythemia Vera: Overview

Polycythemia vera (PV) is a myeloproliferative neoplastic disorder involving uncontrolled red blood cell production resulting in elevated red blood cell (RBC) mass. There is often a concurrent stimulation of myeloid and megakaryocytic lineages, leading to increased white blood cell and platelet production. The current understanding of pathophysiology involves increased sensitivity to growth factors due to an abnormal hematopoietic cell clone. Signs and symptoms, including headache, dizziness, claudication, thrombosis, are a consequence of increased blood viscosity.

The bone marrow of patients with polycythemia vera (PV) contains normal stem cells and contains abnormal clonal stem cells that suppress normal stem cell growth and maturation. The cause of panmyelosis is unregulated neoplastic proliferation. JAK2 kinase mutation likely leads to the signaling derangements resulting in PV. A valine to phenylalanine substitution at position 617 of the JAK2 gene, or JAK2V617F, leads to constitutively active cytokine receptors. This mutation is observed in over 90% of patients with PV and 50% to 60% of primary myelofibrosis, and 50% of essential thrombocythemia. This process leads to increased production of red blood cells and platelets with associated complications of thrombosis and bleeding.

The etiology of the disease process appears to be neoplastic proliferation. There is a signaling defect leading to an abnormal response to growth factors, and the abnormal clonal line interferes with normal lineage proliferation. The Janus kinase-2 (JAK2) gene involved with intracellular signaling is mutated in 90% of cases of polycythemia vera (PV). Cytogenetic studies show the presence of an abnormal karyotype in the hematopoietic progenitor cells in approximately 34% of patients with PV. At the time of diagnosis, 20% of patients have cytogenetic abnormalities, increasing to more than 80% for those with more than 10 years of follow-up care.

The diagnosis of Polycythemia Vera has evolved from the older PVSG criteria to the updated WHO 2016 guidelines. Earlier criteria relied on increased red cell mass, oxygen saturation, splenomegaly, and supportive hematologic parameters, but are now less commonly used due to practical limitations. The current WHO criteria require either all three major criteria or two major plus one minor criterion for diagnosis. Major criteria include elevated hemoglobin/hematocrit levels, bone marrow hypercellularity with trilineage proliferation, and the presence of JAK2 mutations. A low serum erythropoietin level serves as the minor criterion. Importantly, these criteria are applied only after excluding secondary causes of polycythemia. There is no cure for polycythemia vera (PV); treatment goals are aimed at symptom relief and reducing the risk of disease complications, including thrombosis, bleeding, and hematologic transformation. There are currently no means for preventing transformation into myelofibrosis or acute leukemia/myelodysplastic syndrome, but there are known agents to avoid that can increase this risk.

"Polycythemia Vera - Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polycythemia Vera pipeline landscape is provided which includes the disease overview and Polycythemia Vera treatment guidelines. The assessment part of the report embraces, in depth Polycythemia Vera commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polycythemia Vera collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Polycythemia Vera R&D. The therapies under development are focused on novel approaches to treat/improve Polycythemia Vera.

Polycythemia Vera Emerging Drugs Chapters

This segment of the Polycythemia Vera report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Polycythemia Vera Emerging Drugs

• Bomedemstat: Merck Sharp & Dohme LLC

Bomedemstat (MK-3543) is an investigational small molecule, irreversible LSD1 inhibitor being developed by Merck. LSD1 regulates the proliferation of hematopoietic stem cells, playing an essential role in cell differentiation and maturation. Bomedemstat is being evaluated in a wide range of MPNs, including ET, MF and PV. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Polycythemia Vera.

• Flonoltinib: Chengdu Zenitar Biomedical Technology Co., Ltd

Flonoltinib, an orally bioavailable dual inhibitor of both Janus-associated kinase 2 (JAK2) and of FMS-like tyrosine kinase 3 with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon oral administration, flonoltinib targets, binds to and inhibits the activity of both JAK2 and FLT3. This prevents the activation of the JAK/signal transducer and activator of transcription (STAT) signaling pathway and the activation of STAT3 and STAT5 as well as FLT3-mediated signaling. This may lead to an induction of apoptosis and a decrease in proliferation of tumor cells in which JAK2 and FLT3 are overexpressed. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Polycythemia Vera.

• PRT12396: Prelude Therapeutics

PRT12396 is an oral, highly selective, allosteric inhibitor of the mutant JAK2V617F protein, specifically targeting the JH2 (pseudokinase) domain. Developed by Prelude Therapeutics for the treatment of myeloproliferative neoplasms (MPNs), this agent is designed to selectively inhibit cells carrying the mutation while sparing wild-type JAK2, which is expected to improve tolerability and reduce mutant allele burden. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Polycythemia Vera.

Further product details are provided in the report……..

Polycythemia Vera: Therapeutic Assessment

This segment of the report provides insights about the different Polycythemia Vera drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Polycythemia Vera

• There are approx. 20+ key companies which are developing the therapies for Polycythemia Vera. The companies which have their Polycythemia Vera drug candidates in the most advanced stage, i.e. phase III include, Merck Sharp & Dohme LLC.

Phases

The report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Polycythemia Vera pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polycythemia Vera: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polycythemia Vera therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycythemia Vera drugs.

Polycythemia Vera Report Insights

• Polycythemia Vera Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Polycythemia Vera Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Polycythemia Vera drugs?
• How many Polycythemia Vera drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polycythemia Vera?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Polycythemia Vera therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Polycythemia Vera and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck Sharp & Dohme LLC
• Chengdu Zenitar Biomedical Technology Co., Ltd
• Prelude Therapeutics
• Italfarmaco
• Mabwell (Shanghai) Bioscience Co., Ltd.
• Silence Therapeutics plc
• Incyte Corporation
• Hangzhou GluBio Pharmaceutical Co., Ltd.
• Ajax Therapeutics, Inc.
• Syntara

Key Products

• Bomedemstat
• Flonoltinib
• PRT12396
• Givinostat
• 9MW3011
• SLN-124
• INCB000928
• GLB-001
• AJ1-11095
• PXS-5505

This product will be delivered within 1-3 business days.